Becker's Healthcare January 27, 2026
GLP-1 drugs continue to transform care for diabetes, obesity and chronic disease, driving new approvals, pricing debates, coverage shifts and evolving health system strategies.
Since late 2025, developments in the GLP-1 landscape have unfolded on multiple fronts, from novel formulations and payer policy shifts to access challenges and emerging clinical data.
Here’s what you need to know about the latest with GLP-1s:
New drugs and regulatory milestones
GLP-1 therapies continued to hit major regulatory and pipeline milestones in December, reflecting rapid momentum across obesity and diabetes care.
In December, Pfizer struck a $2 billion deal with YaoPharma to develop and commercialize a phase 1 small-molecule GLP-1 receptor agonist for chronic weight management. The agreement includes $150 million upfront and up...
Today's Sponsors
Today's Sponsor